The life science_innovation_roadmap%5b1%5d

11
Arlen D Meyers, MD, MBA University of Colorado School of Medicine CEO, Society of Physician Entrepreneurs

Transcript of The life science_innovation_roadmap%5b1%5d

Page 1: The life science_innovation_roadmap%5b1%5d

Arlen D Meyers, MD, MBAUniversity of Colorado School of Medicine

CEO, Society of Physician Entrepreneurs

Page 2: The life science_innovation_roadmap%5b1%5d

Biomedical and Health InnovationHealth

Digital HealthCare delivery platformsBusiness process innovation

BiomedicalDrugsDevicesDiagnosticsVaccinesCombined products

Page 3: The life science_innovation_roadmap%5b1%5d

Why is bioscience different?IP issuesRegulatory hurdlesHigh riskLong time to marketClinical trial issuesReimbursement issuesChanging business modelsThird party payer issues: Who is the

customer?

Page 4: The life science_innovation_roadmap%5b1%5d

BioentrepreneurshipThe pursuit of biomedical and health

commercial opportunityGoal is to create customer/user/patient

defined valueBy deploying biomedical and health product,

process, systems and service innovationWith uncontrolled resources

Page 5: The life science_innovation_roadmap%5b1%5d

FoundationsIntellectual Property ProtectionRegulatory Affairs and Reimbursement PlanTeamBusiness OpportunitySolution with sustainable competitive

advantage Business model

Page 6: The life science_innovation_roadmap%5b1%5d

3 Phases: SOPEPhase 1: Scoping the opportunity (SO)

Opportunity spotting Idea generation High level Opportunity assessment

Phase 2: Planning, vetting, feasibility, validating (P) Feasibility Analysis Validation and testing

Commercialzation StrategyPhase 3: Executing (E)

Page 7: The life science_innovation_roadmap%5b1%5d

Life Science Innovation Roadmap

Page 8: The life science_innovation_roadmap%5b1%5d

The Capital “Stack”

CapitalValue Advisors, LLC is a registered broker/dealer and member of the Financial Industry Regulatory Authority (FINRA) 8

Type of Capital Pros/ConsSenior Debt - Secured

Non-dilutive, least expensive, but ties up assets – limited amount available

Junior or Mezzanine Debt

May be non-dilutive, more expensive, may not tie up assets

Trade Credit/Credit Cards

More easily available, highest interest rates, non-dilutive

Preferred Equity Allows more debt, more aligned with owners, but dilutive

Common Equity Completely aligned with owners, but most dilutive, possible control issues

[email protected]

Page 9: The life science_innovation_roadmap%5b1%5d

Capital Sources

CapitalValue Advisors, LLC is a registered broker/dealer and member of the Financial Industry Regulatory Authority (FINRA) 9

Amount Growth Buyout

<$1MFriends/FamilySBAHigh Net WorthSmall Local Funds

High Net WorthSmall Local FundsSBA

$1-3MSmall PE FirmsVC FirmsBanks/Mezzanine

Small PE Firms

$3-5MPE FirmsVC FirmsStrategic InvestorsBanks/Mezzanine

PE FirmsStrategic Investors

>$5MPE FirmsVC FirmsStrategic InvestorsBanks/Mezzanine

PE FirmsStrategic Investors

Page 10: The life science_innovation_roadmap%5b1%5d

Financing Biomedical ventures Research

Mostly government basic science grantsDevelopment

Family, friends, foolsSBIR/STTRAngels and angel networksProof of concept awardsState development awardsBusiness plan competitionsCollaborative research and development grants

(CRADA)Crowdfunding sites like http://medstartr.comAccelerators like http://www.blueprinthealth.com

Page 11: The life science_innovation_roadmap%5b1%5d

Financing Biomedical VenturesCommercialization

IPO’sStrategic partnershipsCorporate Venture FundsVC’sReverse mergers/PIPE’s